Clinical Trial Detail

NCT ID NCT04052204
Title Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Pfizer
Indications

head and neck squamous cell carcinoma

prostate cancer

Therapies

Avelumab + NKTR-214

Avelumab + NKTR-214 + Talazoparib

Avelumab + Enzalutamide + NKTR-214

Age Groups: senior adult

No variant requirements are available.